tbuckley/cabot-search huggingface dataset:
Control of Cell Growth. II. Requirement of Thyroid Hormones for the In Vivo EstrogenDependent Growth of Rat Pituitary Tumor Cells2
Authors: Joseph M. Sorrentino, Willis L. Kirkland, David A. Sirbasku
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Control of Cell Growth. II. Requirement of Thyroid Hormones for the In Vivo EstrogenDependent Growth of Rat Pituitary Tumor Cells Get access Joseph M. Sorrentino, Joseph M. Sorrentino Search for other works by this author on: Oxford Academic PubMed Google Scholar Willis L. Kirkland, Willis L. Kirkland Search for other works by this author on: Oxford Academic PubMed Google Scholar David A. Sirbasku David A. Sirbasku 7 7Address reprint requests to Dr Sirbasku. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 6, June 1976, Pages 1155–1158, https://doi.org/10.1093/jnci/56.6.1155 Published: 01 June 1976 Article history Received: 08 July 1975 Accepted: 10 December 1975 Published: 01 June 1976
Expression of ERCC1 in triple-negative breast cancer.
Authors: C. Ozkan, B. Gumuskaya, S. Yaman, S. Aksoy, G. Guler, M. K. Altundag
Journal: Journal of Clinical Oncology (2010)

e11064 Background: Triple-negative breast cancer (TNBC) comprises 15% of breast cancers. Since TNBC lack the available targets of treatment, cytotoxic therapy is the standard approach. Platinum-based chemotherapy regimens seem promising in this setting. Excision repair cross-complementation group 1 (ERCC1) which is a component of nucleotide excision repair (NER) pathway removes platinum induced DNA adducts. Over expression of ERCC1 has been associated with resistance to platinum-based chemotherapy in ovarian and lung cancers. Detecting ERCC1 over expression is important in planning treatment options for TNBC and conducting trials that are investigating specific chemotherapy regimen for TNBC. Methods: Monoclonal antibody against ERCC1 (clone 8F1, Neomarkers) was used for analyzing immunohistochemical expression of ERCC1. Two experienced pathologists blinded to clinical data evaluated ERCC1 expression in 45 TNBC patients' tumor samples. A semi-quantitative H score was calculated by multiplying staining intensity with extent score. Tumors with H-score ≥ 1 classified as ERCC1 positive. Results: Positive ERCC1 expression was found in 73.3% of the tumor samples with an H score ≥ 1 and 26.7% of the tumor samples stained negative with an H score less than 1. 15.5% of the tumor samples stained diffusely and intensively with ERCC1 antibody. Higher ERCC1 expression tended to be correlated with tumor grade (Pearson's correlation coefficient, 0.22; p = 0.14) and family history of cancer (Pearson's correlation coefficient, 0.29; p = 0.053). ERCC1 expression was not correlated with any of the following clinical parameters; age at diagnosis, menopausal status, stage, history of cancer, recurrence in follow-up period. Conclusions: Our results demonstrate that about two thirds of the TNBC showed a relevant expression of ERCC1 that may be predictive of a poor response to platinum-based chemotherapies. Dysfunction of other DNA repair enzymes such as inactivation of BRCA-1 may explain higher sensitivity to cisplatin in TNBC patients. No significant financial relationships to disclose.
PARATYPHOID BACILLUS B IN CANNED RIPE OLIVES
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Deletion in the Canine POMC Gene Is Associated with Weight and Appetite in Obesity-Prone Labrador Retriever Dogs
Authors: Eleanor Raffan, Rowena J. Dennis, Conor J. O’Donovan, Julia M. Becker, Robert A. Scott, Stephen P. Smith, David J. Withers, Claire J. Wood, Elena Conci, Dylan N. Clements, Kim M. Summers, Alexander J. German, Cathryn S. Mellersh, Maja L. Arendt, Valentine P. Iyemere, Elaine Withers, Josefin Söder, Sara Wernersson, Göran Andersson, Kerstin Lindblad-Toh, Giles S.H. Yeo, Stephen O’Rahilly
Journal: Cell Metabolism (2016)

Sequencing of candidate genes for obesity in Labrador retriever dogs identified a 14 bp deletion in pro-opiomelanocortin (POMC) with an allele frequency of 12%. The deletion disrupts the β-MSH and β-endorphin coding sequences and is associated with body weight (per allele effect of 0.33 SD), adiposity, and greater food motivation. Among other dog breeds, the deletion was only found in the closely related flat-coat retriever (FCR), where it is similarly associated with body weight and food motivation. The mutation is significantly more common in Labrador retrievers selected to become assistance dogs than pets. In conclusion, the deletion in POMC is a significant modifier of weight and appetite in Labrador retrievers and FCRs and may influence other behavioral traits.
Platelet monoamine oxidase in chronic schizophrenic patients
Authors: P A Berger, R A Ginsburg, J D Barchas, D L Murphy, R J Wyatt
Journal: American Journal of Psychiatry (1978)

The authors investigated platelet monoamine (MAO) activity in 40 chronic schizophrenic patients, 55 normal control subjects, and 16 hospitalized control subjects. The mean platelet MAO activity for the chronic schizophrenic patients was significantly lower than the mean in either control group. There were no significant differences between the mean platelet MAO activities in 21 chronic paranoid schizophrenic patients compared with 18 chronic undifferentiated schizophrenic patients.
Review of behavioral psychotherapy, I: Obsessive-compulsive disorders
Authors: I M Marks
Journal: American Journal of Psychiatry (1981)

Obsessive-compulsive ritualizers have maintained their improvement after exposure in vivo for up to 3 years' follow-up in the United States, Britain, Greece, and Australia. Unlike exposure in vivo, relaxation is of little value. Early gains in treatment predict long-term outcome. Exposure therapy is usually on an outpatient basis and takes 1-30 sessions. Self-exposure homework is critical. Sessions at home are also required, together with relatives cooperating as exposure cotherapists. Some patients can treat themselves almost unaided, while others need extensive assistance. Clomipramine is helpful for ritualizers with coexisting depression, but depression tends to recur when clomipramine therapy is stopped.
Prevalence and Predictors of Generic Drug Skepticism Among Physicians
Authors: Aaron S. Kesselheim, Joshua J. Gagne, Wesley Eddings, Jessica M. Franklin, Kathryn M. Ross, Lisa A. Fulchino, Eric G. Campbell
Journal: JAMA Internal Medicine (2016)

James S. Yeh, MD, MPH; Jessica M. Franklin, PhD; Jerry Avorn, MD; Joan Landon, MPH; Aaron S. Kesselheim, MD, JD, MPH
P94 Effect of Hydroxyurea on Nocturnal and Awake Oxygen Saturation in Children with Sickle Cell Disease: Abstract P94 Table 1
Authors: L van Geyzel, B Singh, M Akthar, G Ruiz, B Inusa, D Rees, A Gupta
Journal: Thorax (2015)

<h3>Introduction</h3> Sickle cell disease (SCD) causes lifelong morbidity and reduced life expectancy. Resting hypoxaemia and intermittent nocturnal oxygen desaturation are often seen in children with SCD, which may contribute to morbidity associated with vaso-occlusive episodes. Treatment with hydroxyurea reduces the frequency and severity of vaso-occlusive episodes<sup>1</sup> but the impact of hydroxyurea on oxygen saturation and sleep apnoea is unknown. <h3>Objective</h3> To look for any difference in baseline oxygen saturation asleep and awake and the frequency of intermittent nocturnal desaturation after starting hydroxyurea in children with SCD. <h3>Methods</h3> A retrospective review of children who were commenced on hydroxyurea between March 2006 and July 2014 attending two UK sickle-respiratory clinics. Data was collected from overnight sleep studies and averaged pulse oximeter spot check recordings in clinic notes when awake from a) 6 months before starting hydroxyurea and b) up to 2 years after. Lung function and haemoglobin changes were also noted over the same time periods. <h3>Results</h3> Forty six children (25 male) with a median age of 10 years (range 5–19 years) were started on hydroxyurea. Haemoglobin and HbF rose significantly on hydroxyurea as expected (Table 1). After starting hydroxyurea the average overnight oxygen saturation increased from median of 93.5% to 95.2% (p = 0.01) and the median daytime spot oxygen saturation rose from 93.5% to 96.3% (p = 0.001). There was no significant change in the median intermittent nocturnal 3% oxygen desaturation index (ODI), nocturnal PCO<sub>2</sub> or spirometry. <h3>Conclusion</h3> In children with SCD, the use of hydroxyurea was associated with a significant increase in awake and nocturnal baseline oxygen saturation, but no change in intermittent nocturnal desaturation indices or lung function. This preliminary data suggests that improving oxygen saturation may be an important outcome of hydroxyurea therapy with potential benefits in reducing not only vaso-occlusive crises but future respiratory morbidities. This hypothesis would need to be tested by a prospective multicenter trial. <h3>Reference</h3> 1 Charache S, Terrin ML, Moore RD, <i>et al</i>. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. <i>Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med</i> 1995;<b>332</b>:1317–1322
Two Distinct Pathways of Interleukin-5 Synthesis in Allergen-Specific Human T-Cell Clones Are Suppressed by Glucocorticoids
Authors: Akio Mori, Osamu Kaminuma, Matsunobu Suko, Satoshi Inoue, Takeo Ohmura, Akihiko Hoshino, Yumiko Asakura, Keiji Miyazawa, Toyokazu Yokota, Yasushi Okumura, Koji Ito, Hirokazu Okudaira
Journal: Blood (1997)
<i>In Situ</i>Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
Authors: Zachary S. Morris, Emily I. Guy, David M. Francis, Monica M. Gressett, Lauryn R. Werner, Lakeesha L. Carmichael, Richard K. Yang, Eric A. Armstrong, Shyhmin Huang, Fariba Navid, Stephen D. Gillies, Alan Korman, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel
Journal: Cancer Research (2016)

Interest in combining radiotherapy and immune checkpoint therapy is growing rapidly. In this study, we explored a novel combination of this type to augment antitumor immune responses in preclinical murine models of melanoma, neuroblastoma, and head and neck squamous cell carcinoma. Cooperative effects were observed with local radiotherapy and intratumoral injection of tumor-specific antibodies, arising in part from enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). We could improve this response by combining radiation with intratumoral injection of an IL2-linked tumor-specific antibody (termed here an immunocytokine), resulting in complete regression of established tumors in most animals associated with a tumor-specific memory T-cell response. Given the T-cell response elicited by combined local radiation and intratumoral immunocytokine, we tested the potential benefit of adding this treatment to immune checkpoint blockade. In mice bearing large primary tumors or disseminated metastases, the triple-combination of intratumoral immunocytokine, radiation, and systemic anti-CTLA-4 improved primary tumor response and animal survival compared with combinations of any two of these three interventions. Taken together, our results show how combining radiation and intratumoral immunocytokine in murine tumor models can eradicate large tumors and metastases, eliciting an in situ vaccination effect that can be leveraged further by T-cell checkpoint blockade, with immediate implications for clinical evaluation. Cancer Res; 76(13); 3929-41. ©2016 AACR.
HLA Polymorphisms and Epstein-Barr Virus Infection In The Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Ren Lin, Qian Fan, Sijian Yu, Zhiping Fan, Yu Zhang, Fen Huang, Hongsheng Zhou, Li Xuan, Meiqing Wu, Xutao Guo, Min Dai, Jing Sun, Qifa Liu
Journal: Blood (2013)
The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke
Authors: Ralph L. Sacco, Gregory A. Roth, K. Srinath Reddy, Donna K. Arnett, Ruth Bonita, Thomas A. Gaziano, Paul A. Heidenreich, Mark D. Huffman, Bongani M. Mayosi, Shanthi Mendis, Christopher J.L. Murray, Pablo Perel, Daniel J. Piñeiro, Sidney C. Smith, Kathryn A. Taubert, David A. Wood, Dong Zhao, William A. Zoghbi
Journal: Circulation (2016)

In 2011, the United Nations set key targets to reach by 2025 to reduce the risk of premature noncommunicable disease death by 25% by 2025. With cardiovascular disease being the largest contributor to global mortality, accounting for nearly half of the 36 million annual noncommunicable disease deaths, achieving the 2025 goal requires that cardiovascular disease and its risk factors be aggressively addressed. The Global Cardiovascular Disease Taskforce, comprising the World Heart Federation, American Heart Association, American College of Cardiology Foundation, European Heart Network, and European Society of Cardiology, with expanded representation from Asia, Africa, and Latin America, along with global cardiovascular disease experts, disseminates information and approaches to reach the United Nations 2025 targets. The writing committee, which reflects Global Cardiovascular Disease Taskforce membership, engaged the Institute for Health Metrics and Evaluation, University of Washington, to develop region-specific estimates of premature cardiovascular mortality in 2025 based on various scenarios. Results show that &gt;5 million premature CVD deaths among men and 2.8 million among women are projected worldwide by 2025, which can be reduced to 3.5 million and 2.2 million, respectively, if risk factor targets for blood pressure, tobacco use, diabetes mellitus, and obesity are achieved. However, global risk factor targets have various effects, depending on region. For most regions, United Nations targets for reducing systolic blood pressure and tobacco use have more substantial effects on future scenarios compared with maintaining current levels of body mass index and fasting plasma glucose. However, preventing increases in body mass index has the largest effect in some high-income countries. An approach achieving reductions in multiple risk factors has the largest impact for almost all regions. Achieving these goals can be accomplished only if countries set priorities, implement cost-effective population wide strategies, and collaborate in public-private partnerships across multiple sectors.
RiboDB Database: A Comprehensive Resource for Prokaryotic Systematics
Authors: Frédéric Jauffrit, Simon Penel, Stéphane Delmotte, Carine Rey, Damien M. de Vienne, Manolo Gouy, Jean-Philippe Charrier, Jean-Pierre Flandrois, Céline Brochier-Armanet
Journal: Molecular Biology and Evolution (2016)

Ribosomal proteins (r-proteins) are increasingly used as an alternative to ribosomal rRNA for prokaryotic systematics. However, their routine use is difficult because r-proteins are often not or wrongly annotated in complete genome sequences, and there is currently no dedicated exhaustive database of r-proteins. RiboDB aims at fulfilling this gap. This weekly updated comprehensive database allows the fast and easy retrieval of r-protein sequences from publicly available complete prokaryotic genome sequences. The current version of RiboDB contains 90 r-proteins from 3,750 prokaryotic complete genomes encompassing 38 phyla/major classes and 1,759 different species. RiboDB is accessible at http://ribodb.univ-lyon1.fr and through ACNUC interfaces.
Fine Structure of Spontaneous and Estrogen-Induced Secretion in Breast Tumors in the Rat Induced by 7,12-Dimethylbenz[&lt;italic&gt;a&lt;/italic&gt;]anthracene&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Francis L. Archer
Journal: JNCI Journal of the National Cancer Institute (1969)

A small proportion of the breast tumors induced in the rat by 7,12-dimethylbenz[a]anthracene (DMBA) take on the gross and histologic features of secretory activity. A larger proportion of tumors undergo this change when estradiol is administered to tumor-bearing animals after ovariectomy. This histologic appearance is accompanied by alterations in fine structure strongly suggestive of active secretion of protein and lipid. Large, lipid-filled vacuoles formed, many electron-dense droplets appear within dilated cisternae, and membrane-attached ribosomes increase markedly. Thus the tumors' ultrastructural features come to resemble those of secreting breast tissue of pregnant rats, and suggest that the secretion in the DMBA-induced tumor contains milk protein, and represents induction of true differentiation in a neoplasm. Myoepithelium is regularly present in DMBA-induced breast tumors and appears to maintain its relationship to basement membrane. It does not take part in the neoplastic process.
A longitudinal study of psychotropic prescriptions in a teaching nursing home
Authors: M S Lantz, A Louis, G Lowenstein, G J Kennedy
Journal: American Journal of Psychiatry (1990)

This study clarifies the methodological pitfalls of using cross-sectional data to characterize episodic and continuous patterns of prescribing psychotropic medications in nursing homes. Although more than half of the residents in a teaching nursing home received a psychotropic drug during their 5 years of residence, less than one-quarter were continuously medicated. The authors conclude that although the rates of psychotropic prescriptions are an important entry point for concerns about quality and appropriateness of psychotropic administration to older nursing home residents, longitudinal studies including the prescribing pattern, indications, and efficacy are needed to determine more clinically meaningful indicators of quality care.
Tumor-Specific Immunogenicity Induced by Chemical Modification
Authors: Arnold E. Eggers
Journal: JNCI Journal of the National Cancer Institute (1976)

C57BL/6J spleen cells were immunized in vitro against cells from a syngeneic 3-methylcholanthrene-induced sarcoma, either modified with diazotized sulfanilic acid or left unmodified. The spleen cells were harvested after 5 days and run in a short-term 51Cr-release assay against unmodified tumor cells as targets. The spleen cells sensitized against the modified but not the unmodified tumor cells were cytotoxic for the unmodified tumor cell targets but not for two other syngeneic tumor cell lines or syngeneic spleen cells, thus indicating the production of tumor-specific cytotoxicity.
Organophosphate Pesticide Exposures, Nitric Oxide Synthase Gene Variants, and Gene–Pesticide Interactions in a Case–Control Study of Parkinson’s Disease, California (USA)
Authors: Kimberly C. Paul, Janet S. Sinsheimer, Shannon L. Rhodes, Myles Cockburn, Jeff Bronstein, Beate Ritz
Journal: Environmental Health Perspectives (2015)

Nitric oxide synthase (NOS) genes are candidates for Parkinson's disease (PD) because NOS enzymes produce nitric oxide (NO), a pro-oxidant that can damage neurons. Widely used organophosphate (OP) pesticides can induce oxidative stress and are reported to increase PD risk. Additionally, two single nucleotide polymorphisms (SNPs) from the PON1 (paraoxonase 1) gene influence the ability to metabolize OPs.Here, we investigated contributions of NOS genes and OP pesticides to PD risk, controlling for PON1 status.In 357 incident PD cases and 495 population controls, we investigated eight NOS SNPs and interactions with both household and ambient agricultural OP exposures assessed with geographic information system (GIS).In comparing PD in homozygous variant carriers of NOS2A rs1060826 versus homozygous wild-type or heterozygotes, we estimate an adjusted odds ratio (OR) of 1.51 (95% CI: 0.95, 2.41). When considering interactions between NOS1 rs2682826 and OP exposure from household use, the OR for frequent OP use alone was 1.30 (95% CI: 0.72, 2.34) and for the CT+TT genotype alone was 0.89 (95% CI: 0.58, 1.39), and for frequent OP use combined with the CT+TT genotype the OR was 2.84 (95% CI: 1.49, 5.40) (interaction p-value 0.04). Similar results were seen for ambient OP exposure. Interactions between OP exposure and three other NOS1 SNPs and a genetic risk score combining all NOS1 SNPs reached statistical significance.We found that OP pesticides were more strongly associated with PD among participants with variant genotypes in NOS1, consistent with the importance of oxidative stress-inducing mechanisms. Our data provide evidence for NOS1 modifying PD risk in OP exposed populations.Paul KC, Sinsheimer JS, Rhodes SL, Cockburn M, Bronstein J, Ritz B. 2016. Organophosphate pesticide exposures, nitric oxide synthase gene variants, and gene-pesticide interactions in a case-control study of Parkinson's disease, California (USA). Environ Health Perspect 124:570-577; http://dx.doi.org/10.1289/ehp.1408976.